Engineered Protein Scaffolds as Next-Generation Therapeutics
- PMID: 31914898
- DOI: 10.1146/annurev-pharmtox-010818-021118
Engineered Protein Scaffolds as Next-Generation Therapeutics
Abstract
The concept of engineering robust protein scaffolds for novel binding functions emerged 20 years ago, one decade after the advent of recombinant antibody technology. Early examples were the Affibody, Monobody (Adnectin), and Anticalin proteins, which were derived from fragments of streptococcal protein A, from the tenth type III domain of human fibronectin, and from natural lipocalin proteins, respectively. Since then, this concept has expanded considerably, including many other protein templates. In fact, engineered protein scaffolds with useful binding specificities, mostly directed against targets of biomedical relevance, constitute an area of active research today, which has yielded versatile reagents as laboratory tools. However, despite strong interest from basic science, only a handful of those protein scaffolds have undergone biopharmaceutical development up to the clinical stage. This includes the abovementioned pioneering examples as well as designed ankyrin repeat proteins (DARPins). Here we review the current state and clinical validation of these next-generation therapeutics.
Keywords: Adnectin; Affibody; Anticalin; DARPin; antibody; immunoglobulin.
Similar articles
-
Engineering of binding functions into proteins.Curr Opin Biotechnol. 2019 Dec;60:230-241. doi: 10.1016/j.copbio.2019.05.007. Epub 2019 Jun 14. Curr Opin Biotechnol. 2019. PMID: 31207556 Review.
-
Engineered protein scaffolds as next-generation antibody therapeutics.Curr Opin Chem Biol. 2009 Jun;13(3):245-55. doi: 10.1016/j.cbpa.2009.04.627. Epub 2009 Jun 6. Curr Opin Chem Biol. 2009. PMID: 19501012 Review.
-
Recent advances in the development of novel protein scaffolds based therapeutics.Int J Biol Macromol. 2017 Sep;102:630-641. doi: 10.1016/j.ijbiomac.2017.04.045. Epub 2017 Apr 13. Int J Biol Macromol. 2017. PMID: 28412342 Review.
-
DARPins: a new generation of protein therapeutics.Drug Discov Today. 2008 Aug;13(15-16):695-701. doi: 10.1016/j.drudis.2008.04.013. Epub 2008 Jul 11. Drug Discov Today. 2008. PMID: 18621567 Review.
-
Advances in the Application of Designed Ankyrin Repeat Proteins (DARPins) as Research Tools and Protein Therapeutics.Methods Mol Biol. 2018;1798:307-327. doi: 10.1007/978-1-4939-7893-9_23. Methods Mol Biol. 2018. PMID: 29868969 Review.
Cited by
-
Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes.Int J Mol Sci. 2021 Nov 6;22(21):12014. doi: 10.3390/ijms222112014. Int J Mol Sci. 2021. PMID: 34769444 Free PMC article.
-
Deploying synthetic coevolution and machine learning to engineer protein-protein interactions.Science. 2023 Jul 28;381(6656):eadh1720. doi: 10.1126/science.adh1720. Epub 2023 Jul 28. Science. 2023. PMID: 37499032 Free PMC article.
-
Design of an artificial phage-display library based on a new scaffold improved for average stability of the randomized proteins.Sci Rep. 2023 Jan 24;13(1):1339. doi: 10.1038/s41598-023-27710-4. Sci Rep. 2023. PMID: 36693880 Free PMC article.
-
Strategy for Avoiding Protein Corona Inhibition of Targeted Drug Delivery by Linking Recombinant Affibody Scaffold to Magnetosomes.Int J Nanomedicine. 2022 Feb 11;17:665-680. doi: 10.2147/IJN.S338349. eCollection 2022. Int J Nanomedicine. 2022. PMID: 35185331 Free PMC article.
-
Improving the pharmacokinetics, biodistribution and plasma stability of monobodies.Front Pharmacol. 2024 Apr 4;15:1393112. doi: 10.3389/fphar.2024.1393112. Front Pharmacol. 2024. PMID: 38617793 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
